Oncternal Therapeutics (ONCT)
(Delayed Data from NSDQ)
$4.95 USD
+0.10 (2.04%)
Updated Aug 23, 2024 03:48 PM ET
2-Buy of 5 2
F Value C Growth F Momentum F VGM
Income Statements
Fiscal Year end for Oncternal Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1 | 1 | 4 | 3 | 2 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 1 | 1 | 4 | 3 | 2 |
Selling & Adminstrative & Depr. & Amort Expenses | 43 | 46 | 36 | 21 | 36 |
Income After Depreciation & Amortization | -42 | -45 | -31 | -18 | -33 |
Non-Operating Income | 2 | 1 | 0 | 0 | -1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -39 | -44 | -31 | -17 | -34 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -39 | -44 | -31 | -17 | -34 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -39 | -44 | -31 | -17 | -34 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -43 | -45 | -31 | -18 | -33 |
Depreciation & Amortization (Cash Flow) | -2 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -42 | -45 | -31 | -18 | -33 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 2.94 | 2.63 | 2.47 | 1.02 | 0.52 |
Diluted EPS Before Non-Recurring Items | -13.43 | -16.80 | -12.80 | -17.00 | -31.20 |
Diluted Net EPS (GAAP) | -13.43 | -16.80 | -12.80 | -17.00 | -66.20 |
Fiscal Year end for Oncternal Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.80 | 0.57 | 0.30 | 0.18 | 0.11 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.80 | 0.57 | 0.30 | 0.18 | 0.11 |
SG&A, R&D, and Dept/Amort Expenses | 9.66 | 9.35 | 9.93 | 10.57 | 9.65 |
Income After SG&A, R&D, and Dept/Amort Expenses | -8.86 | -8.78 | -9.63 | -10.39 | -9.54 |
Non-Operating Income | 0.30 | 0.39 | 0.47 | 0.53 | 0.58 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -8.56 | -8.39 | -9.16 | -9.86 | -8.97 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -8.56 | -8.39 | -9.16 | -9.86 | -8.97 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -8.56 | -8.39 | -9.16 | -9.86 | -8.97 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 2.96 | 2.96 | 2.95 | 2.95 | 2.94 |
Diluted EPS Before Non-Recurring Items | -2.89 | -2.83 | -3.11 | -3.40 | -3.00 |
Diluted Net EPS (GAAP) | -2.89 | -2.83 | -3.03 | -3.40 | -3.00 |